An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy

Journal of General Internal Medicine

Volumn 30, Issue 12, 2015, Pages 1879-1883

  Nichols, Laura ^a   Pfeifer, Kurt ^a   Mammen, Andrew L ^b,c   Shahnoor, Nazima ^a   Konersman, Chamindra G ^a,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti HMGCR antibody; idiopathic inflammatory myopathy; necrotizing autoimmune myopathy; statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A ANTIBODY; ATORVASTATIN; CENTROMERE ANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATINE KINASE; ENZYME ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; PREDNISONE; SIMVASTATIN; UNCLASSIFIED DRUG; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; AUTOANTIBODY;

ADULT; AFRICAN AMERICAN; ARTICLE; CASE REPORT; COLONOSCOPY; CORONARY STENTING; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROMYOGRAM; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MIDDLE AGED; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NECROTIZING AUTOIMMUNE MYOPATHY; NERVE CONDUCTION; POLYMYOSITIS; SIDE EFFECT; AUTOIMMUNE DISEASE; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; MUSCLE DISEASE; PATHOLOGY; SKELETAL MUSCLE;

ACYL COENZYME A; ATORVASTATIN CALCIUM; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CREATINE KINASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 84946499756     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3303-9     Document Type: Article

References (19)

1. Stagnitti M. Trends in Statins Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population, 2000 and 2005: Statistical Brief #205. Agency for Healthcare Research and Quality Medical Expenditure Panel Survey. 2008.
2. Loannidis JPA. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014;311(5):463–4.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279(20):1615–22.
4. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria. Lancet. 2003;361(9364):1149.
5. Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: a review. Muscle Nerve. 2013;48(4):477–83.
6. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–90.
7. Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337:1159–1162.
8. Padala S, Thompson PD. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis. 2012;222(1):15–21.
9. Zaraa IR, Labene I, Mrabet D, et al. Simvastatin-induced dermatomyositis in a 50-year-old man. BMJ Case Rep. 2011;29:1–4.
10. Needham M, Fabian V, Knezevic W. Progressive myopathy with up-regulation of MHC-1 associated with statin therapy. Neuromuscul Disord. 2007;17:194–200.
11. Dubowitz, V, Sewry, CA, Oldfors, A. Muscle Biopsy: A Practical Approach. 4th Ed. Saunders, Elsevier Ltd; 2013:517.
12. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–66.
13. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 2012;64(8):1233–7.
14. Mammen AL, Pak K, Williams E, et al. Rarity of anti–3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64(2):269–72.
15. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.
16. Lianga C, Needhama M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011;23:612–9.
17. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS One. 2008;3(6):e2522.
18. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185–90.
19. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8A):69C–76C.